CLASS II Drug recall · Reported 4 May 2022 · FDA Enforcement Report

Losartan Potassium, a) blister card recalled by RemedyRepack

RemedyRepack is recalling Losartan Potassium, a) blister card (, distributed in Alaska, Pennsylvania. The recall was initiated on 6 Apr 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot # B1467803-120621, exp. date 06/30/2022 Lot # J0585793-121721, exp. date 12/31/2022
NDC70518-3282
Quantity recalled433/30 count blister cards, 33/60 count blister cards

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0788-2022
FDA event ID
89968
Recalling firm
RemedyRepack, Indiana, PA
Manufacturer
REMEDYREPACK INC.
Classification
Class II
Status
Terminated
Recall initiated
6 Apr 2022
FDA classified
26 Apr 2022
Reported
4 May 2022
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Potency & Assay

Timeline

6 Apr 2022Recall initiated by company
26 Apr 2022Classified by FDA+20 days
4 May 2022Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Losartan Potassium 50 mg Tablet, a) 30-count blister card (NDC# 70518-3282-1), b) 60-count blister card (NDC: 70518-3282-0), Rx Only, MFG by: Lupin Pharma, Baltimore, MD 21202.

Where it was distributed

Product was distributed to customers in AK and PA.

AlaskaPennsylvania

Questions about this recall

Why was it recalled?

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits.

Which lots are affected?

Lot # B1467803-120621, exp. date 06/30/2022 Lot # J0585793-121721, exp. date 12/31/2022

Where was it sold?

Product was distributed to customers in AK and PA.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from RemedyRepack

All 61

Other Losartan recalls

All 98
ReportedClassRecallCompanyReasonWhere
DrugCLASS IILosartan Potassium and Hydrochlorothiazide Tablets recalledLosartan Potassium And HydrochlorothiazideMacleods Pharma USAForeign MaterialNationwide
DrugCLASS IILosartan Potassium Tablets, USP, 25 mg recalled by Strides PharmaLosartan PotassiumStrides PharmaForeign MaterialNationwide
DrugCLASS IILosartan potassium & Hydrochlorothiazide Tablets 100 mg/25 recalledLosartan Potassium And HydrochlorothiazideMacleods Pharma UsaPotency & AssayNationwide
DrugCLASS IILosartan Potassium Tablets, USP 25 mg recalled by PD-Rx PharmaceuticalsLosartan PotassiumPD-Rx PharmaceuticalsPotency & AssayNationwide
DrugCLASS IILosartan Potassium Tablets, USP 100 mg recalled by PD-Rx PharmaceuticalsLosartan PotassiumPD-Rx PharmaceuticalsPotency & AssayNationwide